SOD1 and amyotrophic lateral sclerosis: Some gene–target therapies have been conducted in clinical research such as antisense oligonucleotide (ASO) silencing for SOD1 mutation, fused in sarcoma gene (FUS) mutation in ALS (Miller et al., 2020; Korobeynikov et al., 2022), as well as targeting protein apoE with antibodies to inhibit amyloid accumulation in AD (Liao et al., 2018).